Actavis CEO: We may be big, but we don't want to be Big Pharma

Big Pharma or "growth pharma"? Actavis ($ACT) CEO Brent Saunders is aiming for the latter. Though his company is expected to rank among the industry's top 10 after closing its Allergan ($AGN) buy later this year, Saunders says Actavis won't act like a Big Pharma. What's the difference? He has some ideas. Report